AFT Pharmaceuticals Full Year 2024 Earnings: EPS: NZ$0.15 (vs NZ$0.10 in FY 2023)

Simply Wall St

May 23, 2024

AFT Pharmaceuticals (NZSE:AFT) Full Year 2024 Results

Key Financial Results

Revenue: NZ$195.4m (up 25% from FY 2023).
Net income: NZ$15.6m (up 47% from FY 2023).
Profit margin: 8.0% (up from 6.8% in FY 2023). The increase in margin was driven by higher revenue.
EPS: NZ$0.15 (up from NZ$0.10 in FY 2023).

earnings-and-revenue-growth — NZSE:AFT Earnings and Revenue Growth May 23rd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

AFT Pharmaceuticals Earnings Insights

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 35% growth forecast for the Pharmaceuticals industry in Oceania.

Performance of the market in New Zealand.

The company's shares are up 11% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on AFT Pharmaceuticals' balance sheet health.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.